Results 201 to 210 of about 4,204,588 (241)

The fc fragment of IgMs binds C1q to activate the first step of the classical complement pathway, while inhibiting complement-dependent cytotoxicity. [PDF]

FEBS J
Pinto AJ, Chouquet A, Bally I, Rossi V, Thielens NM, Dumestre-Pérard C, Kunert R, Gaboriaud C, Ling WL, Reiser JB.   +9 more
europepmc   +1 more source

Phylogenetic and Genomic Characterization of Whole Genome Sequences of a Herpes Simplex Virus Type 1 Isolate Identified Genomic Variant Characteristics in a Human Subject with Fulminant Hepatitis. [PDF]

Int J Mol Sci
Smirne C, Romano G, Ravanini P, Crobu MG, Palumbo A, Ferrari G, Mercandino A, Grossini E, Pirisi M, Piralla A.   +9 more
europepmc   +1 more source

Ocular Half-Life: What it Does and Does Not Mean for Intravitreal Anti-angiogenic Drug Durability. [PDF]

Ophthalmol Ther
Avery R, Diack C, Holekamp N, Lhor M, Mar F, Maass K.   +5 more
europepmc   +1 more source

Using Synthetic Glycans to Investigate Anti‐Glycan Antibodies and Explore Their Medical Potential

Angewandte Chemie International Edition, EarlyView.
Anti‐glycan antibodies are essential in health and disease. Access to novel glycan structures paves the way for progress in antibody profiling for biomarker discovery, antibody development, and vaccine design. We summarize the strategies to synthesize and utilize synthetic glycans for the development and application of anti‐glycan antibodies in basic ...
Fabienne Weber, Aina Valenti, Jiří Ledvinka, Oren Moscovitz, Peter H. Seeberger   +4 more
wiley   +1 more source

Fully human anti-FOLR1 T-cell engager demonstrates potent activity in CBFA2T3::GLIS2 acute megakaryoblastic leukemia. [PDF]

Blood Neoplasia
Morris SM, Pilat K, Girard EJ, Noll A, Ang LS, Price J, Mhyre AJ, Correnti CE, Bandaranayake AD, Mehlin C, Clarke M, Brasel K, Muthuraman P, Crook ZR, Cole B, Hylkema TA, Le Q, Meshinchi S, Olson JM.   +18 more
europepmc   +1 more source

In Silico to In Cerebro—Development of the Orexin Receptor Antagonist “Photorexant” for Photomodulation In Vitro and in Mouse Brains

Angewandte Chemie International Edition, EarlyView.
Following a structure‐based design approach, photoswitchable derivatives of the FDA‐approved drug suvorexant were designed, docked, synthesized, and characterized pharmacologically at the orexin 1 and 2 receptors (OX1R and OX2R). Optimized “photorexant” showed up to an 11‐fold difference in IC50 between photoisomers, enabled dynamic and reversible ...
Marcus Angermann, Marie H. Deventer, Vicente Ledesma‐Martin, Nuno Martinho, Alix Flake, Silvia Mori, Angel Nuñez, Jaime Pignatelli, Rita C. Guedes, Christophe P. Stove, Michael Decker   +10 more
wiley   +1 more source

Artificial intelligence advancements in monoclonal antibody development technology. [PDF]

Front Immunol
Ammar M, Samsonov M, Gurylina E, Bayzigitov D.   +3 more
europepmc   +1 more source

Uncaging Iridium(III) Complexes for Combined Photodynamic and Photoactivated Chemotherapy

Angewandte Chemie International Edition, EarlyView.
Light‐activatable iridium(III) anticancer prodrugs demonstrate how chalcogen coordination controls photoinduced therapeutic activity. Upon visible‐light irradiation, sulfur‐ and selenium‐based caging ligands undergo distinct oxygen‐dependent photoreactions that trigger ligand release and singlet oxygen generation, enabling combined photoactivated ...
Victoria V. L. Müller, Dominik Moreth, Irene Regeni, Lan Wang, Sylvestre Bonnet, Ulrich Schatzschneider   +5 more
wiley   +1 more source

Fusion Protein Technology to Enhance Pharmacological Properties of L-Asparaginases. [PDF]

Biomolecules
Shishparenok AN, Blinova VG, Zhdanov DD.
europepmc   +1 more source

Fibrillisation and Mechanical Properties of Plasma‐Treated Modification LDPE/PA6 Microfibrillar Composites

Journal of Applied Polymer Science, EarlyView.
Plasma treatment enhances interfacial adhesion between LDPE/PA6 via carbonyl group formation. PA6 droplet size heterogeneity reduced to ~850 nm after plasma treatment. Drawing at 160°C produces highly oriented microfibrils with faster throughput. Plasma‐treated MFCs show up to 500% tensile strength increase and 18% higher stiffness.
Narges Gray, Maximillian Pitto, Nam Kyeun Kim, Casparus Johannes Reinhard Verbeek, Simon Bickerton   +4 more
wiley   +1 more source